Potential Synergies & Collaborative Opportunities
| Collaborative Objectives | Short-Term (Quick wins in service mode) | Mid/Long-Term (Shared-risk Mode) | |
|---|---|---|---|
| Screening opportunities | Screening & profiling of Pharma NCE hits/leads in primary cells & co-cultures (2D, 3D etc.,) | Generation of customized libraries of “phenotypically active” molecules/fragments using primary cell-based models | |
| Translational Paradigms | Mechanistic profiling of hits/leads in primary cells & co-culturesDerivation/optimization of primary tumors for mouse xenograft studies | Profiling leads/hits in Saarum’s EMT model & derivativesCo-development of other phenotypic models
Generation of CSCs/CTC paradigms for screening & profiling hits/leads |
|
| Target/Biomarker ID & Validation | Biomarker/Target ID & validation in FFPE & Fresh samples | Development of novel/custom paradigms using primary cells for biomarker/Target ID & validation Collaboratively mine Sapien’s sample sets for diagnostic markers |
|
| Toxicology Platforms | Safety screening of hits/leads in specific primary cell types (ES/MSCs, PBMCs etc.) | Co-development & integration of ES/iPS-derived liver/cardiac/neuro tox paradigms into the NCE/NBE discovery workflow. | |
Your message was successfully sent. Thank You!